![]()
|
|
||||||||
J. Biol. Chem., Vol. 262, Issue 16, 7455-7462, Jun, 1987
K Marien, R Moyer, P Loveland, K Van Holde and G Bailey
The covalent binding of the activated forms of several aflatoxins to N- 7 of guanine residues on purified DNA has been studied. The aflatoxins include aflatoxin B1 (AFB1) and two human metabolites, aflatoxicol and aflatoxin M1, along with aflatoxicol M1, a rabbit and trout metabolite. DNA binding studies using tritiated [3H]aflatoxins indicate that equimolar solutions of each aflatoxin upon activation with chloroperoxybenzoic acid readily react to produce covalently bound adducts. These reactions produce alkali-labile sites which can be identified using a simple variation of the Maxam-Gilbert sequencing procedure. Two DNA fragments were exposed to each aflatoxin, and the reaction intensities at 33 guanine residues were determined. As much as 10-fold variation in reaction intensities was observed for various guanyl sites. Data indicate that none of the aflatoxins had identical reaction profiles, although AFB1 and aflatoxicol M1 were similar, as were aflatoxicol and aflatoxin M1. Hence, the frequency with which the various aflatoxin epoxides might damage specific sites critical for tumor initiation in vivo would not be predictable from total covalent binding indices. The frequency of occurrence of modifications at particular sites for AFB1 was also compared with the empirical "rules" established for AFB1 by Misra et al. (Misra, R. P., Muench, K. F., and Humayun, M. Z. (1983) Biochemistry 22, 3351-3359). Identical sites within fragments were compared for each aflatoxin, and the data showed that the attacking frequency for some such sites varied significantly. These results indicate that binding intensity rules based on nearest neighbor nucleotides do not reliably predict guanyl-AFB1 binding frequencies.
This article has been cited by other articles:
![]() |
C. R. Madden, M. J. Finegold, and B. L. Slagle Altered DNA Mutation Spectrum in Aflatoxin B1-Treated Transgenic Mice That Express the Hepatitis B Virus X Protein J. Virol., October 11, 2002; 76(22): 11770 - 11774. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Smela, M. L. Hamm, P. T. Henderson, C. M. Harris, T. M. Harris, and J. M. Essigmann The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma PNAS, May 14, 2002; 99(10): 6655 - 6660. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Smela, S. S. Currier, E. A. Bailey, and J. M. Essigmann The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis Carcinogenesis, April 1, 2001; 22(4): 535 - 545. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |